BICRA

Across TCGA pan-cancer cohorts, BICRA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BICRA data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BICRA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BICRA expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where BICRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.766	0.484	.001	48	view →
HNSC	DFS	Tertile	II,III,IV	0.740	0.908	.005	16	view →
CCRCC	OS	Quartile	All	1.000	0.565	.004	15	view →
LSCC	OS	Median	III,IV	0.878	0.412	.008	14	view →
PDAC	DFS	Quartile	All	0.849	0.638	.024	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BICRA–LUAD (DFS)

Open the LUAD breakdown →